Evaluation of Fast Molecular Detection of Lymph Node Metastases in Prostate Cancer Patients Using One-Step Nucleic Acid Amplification (OSNA)
- PMID: 33807774
- PMCID: PMC7961354
- DOI: 10.3390/cancers13051117
Evaluation of Fast Molecular Detection of Lymph Node Metastases in Prostate Cancer Patients Using One-Step Nucleic Acid Amplification (OSNA)
Abstract
Background: In clinical routine, only fractions of lymph nodes (LNs) are examined histopathologically, often resulting in missed (micro-)metastases and incorrect staging of prostate cancer (PCa). One-step nucleic acid amplification (OSNA) analyzes the entire LN by detecting cytokeratin 19 (CK19) mRNA as a surrogate for LN metastases requiring less effort than conventional biomolecular techniques. We aimed to evaluate performance of OSNA in detecting sentinel LN (SLN) metastases in PCa. Methods: SLNs (n = 534) of 64 intermediate- or high-risk PCa patients undergoing radical prostatectomy with extended and sentinel-guided lymphadenectomy were cut into slices and alternatingly assigned to OSNA and histopathology (hematoxylin-eosin staining, CK19, and CK AE1/AE3 immunohistochemistry). Sensitivity and specificity of OSNA and concordance and measure of agreement (Cohen's kappa (κ)) between OSNA and histopathology were assessed. Results: Histopathology revealed metastases in 76 SLNs. Sensitivity and specificity of OSNA were 84.2% and 96.1%, respectively. Discordant results were recorded for 30 of 534 SLNs, revealing high concordance (94.4%). Twenty-four discordant cases were classified as micrometastases, indicating a possible allocation bias. In 18 cases, positive results were conferred only by OSNA resulting in seven LN-positive patients who were missed by histopathology. Overall, the level of agreement was high (κ = 0.78). Conclusions: OSNA provided a diagnosis that was as least as accurate as detailed histological examination and might improve LN staging in PCa.
Keywords: OSNA; cytokeratin 19; metastases; prostate cancer; sentinel lymph node.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
References
-
- Winter A., Kneib T.H., Wasylow C., Reinhardt L., Henke R.-P., Engels S., Gerullis H., Wawroschek F. Updated nomogram incorporating percentage of positive cores to predict probability of lymph node invasion in prostate cancer patients undergoing sentinel lymph node dissection. J. Cancer. 2017;8:2692–2698. doi: 10.7150/jca.20409. - DOI - PMC - PubMed
-
- Touijer K.A., Karnes R.J., Passoni N., Sjoberg D.D., Assel M., Fossati N., Gandaglia G., Eastham J.A., Scardino P.T., Vickers A., et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: A comparative analysis of different postoperative management strategies. Eur. Urol. 2018;73:890–896. doi: 10.1016/j.eururo.2017.09.027. - DOI - PMC - PubMed
-
- Mottet N., Cornford P., van den Bergh R.C.N., Briers E., De Santis M., Fanti S., Gillessen S., Grummet J., Henry A.M., Lam T.B., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. [(accessed on 26 November 2020)]; Available online: https://uroweb.org/guideline/prostate-cancer/
-
- Hofman M.S., Lawrentschuk N., Francis R.J., Tang C., Vela I., Thomas P., Rutherford N., Martin J.M., Frydenberg M., Shakher R., et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomized, multicenter study. Lancet. 2020;395:1208–1216. doi: 10.1016/S0140-6736(20)30314-7. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
